NeuroControl To Debut StIM Neuromuscular Stimulator In 2001; Study Begins
This article was originally published in The Gray Sheet
Executive Summary
NeuroControl hopes to launch its StIM neuromuscular stimulator next year pending FDA 510(k) clearance for treatment of pain associated with shoulder subluxation after a stroke, the firm says. The Cleveland firm commenced an eight-center U.S. clinical trial following investigational device exemption clearance Aug. 1.